Oppenheimer initiated coverage on TriSalus Life Sciences with a new price target
$TLSI
Medical Specialities
Health Care
Oppenheimer initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $10.00 | Overweight | Cantor Fitzgerald |
| 11/11/2024 | $11.00 | Buy | ROTH MKM |
| 10/25/2024 | $12.50 | Outperform | Northland Capital |
| 9/16/2024 | $10.00 | Outperform | Oppenheimer |
| 5/30/2024 | $12.00 | Buy | Canaccord Genuity |
James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp
TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other
– Accomplished industry veteran brings deep strategic and operational expertise TriSalus Life Sciences® Inc. (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence. "We are thrilled to welcome Liselotte to the TriSalus Board of Directors as we commercialize the TriNav® Infusion System and progress our pipeline through key milestones in
3 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, "Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model," in the peer-reviewed Journal of Vascular and Interventional Radiology. The study, conducted in a transgenic tumor model, highlights the superior performance of the TriNav Infusion System in delivering Embospheres® into liv
James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp
– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da
Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00
ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00
Northland Capital initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $12.50
– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da
Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter results will be issued prior to the call. The event will be webcast live on the investor relations section of TriSalus' website at https://investors.trisaluslifes
Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periods Announces plan to launch the "DELIVER" Program in Q3 2024, clinical trials leveraging the TriNav® Infusion System (TriNav) in complex patient types and aiming to significantly expand the addressable market Expects to report data from phase 1 trials of nelitolimod in uveal melanoma liver metastases and locally advanced pancreatic cancer via its pancreatic infusion technol
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
D - TriSalus Life Sciences, Inc. (0001826667) (Filer)
SCHEDULE 13D/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)